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Background. Secondary hyperparathyroidism (SHPTH) is
highly prevalent among persons with end-stage renal disease
(ESRD). SHPTH has been linked to uremic bone disease, vas-
cular calcification, and a higher risk of death. Parathyroidec-
tomy (PTX) can dramatically reduce parathyroid hormone
(PTH) and phosphate levels; however, the relationship between
PTX and survival is not known.
Methods. We conducted an observational matched cohort
study utilizing data from the United States Renal Database Sys-
tem (USRDS) in which 4558 patients undergoing a first PTX
while on hemodialysis or peritoneal dialysis were individually
matched by age, race, gender, cause of ESRD, dialysis duration,
prior transplantation status, and dialysis modality to 4558 con-
trol patients who did not undergo PTX. Patients were followed
from the date of PTX until they died or were lost to follow-up.
Results. The 30-day postoperative mortality rate following
PTX was 3.1%. Long-term relative risks of death among pa-
tients undergoing PTX were estimated to be 10% to 15% lower
than those of matched control patients not undergoing surgery.
Survival curves between the 2 groups crossed 587 days follow-
ing PTX. Median survival was 53.4 months (95% CI: 51.2–56.4)
in the PTX group, and 46.8 months (95% CI: 44.7–48.9) in the
control group.
Conclusion. PTX was associated with higher short-term, and
lower long-term, mortality rates among U.S. patients receiving
chronic dialysis. Measures to attenuate SHPTH may play an
important role in reducing mortality among patients with end-
stage renal disease.
Secondary hyperparathyroidism (SHPTH) is present
among the majority of patients with end-stage renal dis-
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ease (ESRD) [1]. Excess circulating levels of parathyroid
hormone (PTH), phosphate, and the calcium-phosphate
product have been linked to uremic bone disease, vascu-
lar calcification, and death [2–4]. Standard medical ther-
apy for SHPTH often includes high doses of oral calcium
binders, which have recently been associated with the
extent of vascular calcification [5]. Parathyroidectomy
(PTX) can dramatically lower PTH and phosphate lev-
els, but is typically reserved for patients with refractory
secondary and tertiary hyperparathyroidism [6].
Case series have reported improvements in bone pain,
pruritis, anemia, and hypertension following PTX for re-
nal hyperparathyroidism; however, postoperative deaths
are not uncommon [7–10]. Estimates of long-term mor-
tality rates following PTX are not available due to the
small number of patients and limited follow-up of single-
center studies. Without such information, referral for
PTX is based on a combination of patient symptoms,
serum markers of SHPTH, lack of response to medical
therapy, and the discretion of the practicing physician.
Given the link between SHPTH and adverse cardio-
vascular outcomes, we hypothesized that PTX would be
associated with lower long-term mortality rates. We uti-
lized data from the United States Renal Database System
(USRDS) to estimate postoperative and long-term mor-
tality rates following PTX. We compared short- and long-
term mortality rates among patients undergoing PTX
with a matched cohort of patients not undergoing PTX.
METHODS
Patient population
Data were utilized from the USRDS, which collects
clinical, demographic, and dialysis information for all
patients receiving chronic renal replacement therapy in
the United States. Details of the USRDS are described
elsewhere [11]. Patients were considered for the present
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analysis if they were at least 18 years old and had initiated
renal replacement therapy between January 1, 1988 and
October 1, 1999. Patients who died, were lost to follow-
up, or underwent PTX during the first 90 days of renal
replacement therapy were excluded. The exclusion of the
first 90 days of dialysis time is due to potential delay of
the Medicare eligibility application process, which can
take up to 90 days. Because USRDS hospitalization data
is obtained from Medicare inpatient claims, the study co-
hort was further restricted to patients with fee-for-service
Medicare as their primary payer 90 days after the initi-
ation of dialysis. Payer status was determined from the
longitudinal Payer History file maintained by the USRDS.
Determination of parathyroidectomy
Patients were considered to have undergone PTX if
they received an International Classification of Diseases–
Clinical Modification 9th Edition (ICD9-CM) hospi-
tal procedure code 06.81, “total parathyroidectomy,” or
06.89, “other parathyroidectomy.” The USRDS obtains
hospital procedure codes through Medicare institutional
inpatient claims sourced from the Centers for Medicare
and Medicaid Services (CMS, formerly HCFA). Up to 10
procedure codes were analyzed per hospitalization. The
first PTX occurring between the initiation of dialysis and
December 31, 1999 was utilized for analysis.
Selection of patient cohorts
From the eligible patient population, all dialysis pa-
tients undergoing a first PTX between January 1, 1988
and December 31, 1999 were selected. Because indica-
tions for PTX, as well as the response to PTX, may differ
between dialysis and transplant patients, patients under-
going PTX with a functioning renal transplant were ex-
cluded from the present study.
For each eligible PTX patient, 1 control patient was
selected on the basis of being alive on the PTX date, and
individually matched by age (plus or minus 2 years), race
(African American, Caucasian, other), gender, year of
initiation of dialysis (plus or minus 1 year), primary cause
of ESRD (diabetes, hypertension, glomerulonephritis,
polycystic kidney disease, other), and modality at the time
of PTX (hemodialysis, peritoneal dialysis). For PTX pa-
tients who had previously received a renal transplant, a
similar control patient was found who had also received
a renal transplant, and matched by the transplant date
(plus or minus 1 year).
Determination of risk time
For each matched patient pair consisting of 1 PTX
patient and 1 control patient, the study start date was
defined as the PTX date. Thus, each matched patient
pair began accruing risk time on the date of PTX. Pa-
tients were considered at risk until the first occurrence
of death, loss to follow-up, loss of Medicare coverage, or
the study’s close on December 31, 2001. Transplantation
after PTX was handled as a time-dependent covariate.
Dates of death are obtained by the USRDS from CMS
form #2746, which is completed by the primary nephrol-
ogist following the death of any dialysis patient. Patients
were considered lost to follow-up by the USRDS if they
received no dialysis billing claims for 1 consecutive year
without a notification of death. For patients determined
to be lost to follow-up, the last date of dialysis billing
claims was considered the last date of follow-up. Sur-
vival, follow-up data, and insurance status were complete
through December 31, 2001.
Calcitriol data
Baseline injectable calcitriol use was examined by link-
ing USRDS Medicare institutional claims files to the
study cohort. For each calendar month, calcitriol dose
was calculated by summing the number of injectable 1-lg
units billed during that month. Because claims for cal-
citriol were rare prior to 1993, we limited our subanaly-
ses of calcitriol use to patient pairs with a PTX date after
January 1, 1994.
Statistical analysis
Mortality rates were calculated by dividing the number
of deaths by the number of person-years at risk within
each time period following PTX. Baseline calcitriol
dosages were compared between PTX and non-PTX
groups using the Student t test. Unadjusted Kaplan-Meier
survival curves were constructed by PTX group. Survival
analysis was used to estimate the relationship between
PTX and the instantaneous relative hazard of mortality.
Elapsed time from PTX was modeled as a categorical
time-dependent covariate. Time intervals were chosen as
0 to 30 days, 30 to 90 days, 90 days to 1 year, 1 to 3 years,
and greater than 3 years following PTX to convey short-
term and long-term mortality risks.
Multivariate models were stratified by matched pa-
tient pair to most precisely control for confounding by
the matching variables. In addition to matching, multi-
variate models were adjusted for age and dialysis dura-
tion to correct for slight differences in these continuous
variables within each matched pair. Multivariate mod-
els were further adjusted for dialysis modality follow-
ing PTX (hemodialysis, peritoneal dialysis, transplant),
which was modeled as a time-dependent covariate. Scaled
Schoenfeld residuals and graphical methods were exam-
ined to confirm that assumptions of the proportional haz-
ards model were satisfied within each time interval.
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(PTX) patients undergoing PTXa
(N = 4558) (N = 4558)
Age years 47.6 (15.8) 47.6 (15.8)
Race
White 2221 (48.7) 2221 (48.7)
Black 2212 (48.5) 2212 (48.5)
Other 125 (2.7) 125 (2.7)
Gender
Male 1939 (42.5) 1939 (42.5)
Female 2619 (57.5) 2619 (57.5)
Cause of ESRD
Hypertension 1611 (35.3) 1611 (35.3)
Diabetes 886 (19.4) 886 (19.4)
Glomerulonephritis 986 (21.6) 986 (21.6)
Polycystic disease 207 (4.5) 207 (4.5)
Other 868 (19.0) 868 (19.0)
Duration of dialysis years 3.4 (2.2) 3.3 (2.2)
Modality at PTX
Hemodialysis 3769 (82.7) 3769 (82.7)
Peritoneal dialysis 789 (17.3) 789 (17.3)
Prior renal transplant 220 (4.8) 220 (4.8)
All values expressed as mean (SD) or N (%).
aControl patients individually matched to PTX patients by all characteristics
listed in the Table, plus the date of initiation of renal replacement therapy and
the date of prior renal transplantation, if applicable.
RESULTS
Data were available for 769,179 ESRD patients ini-
tiating renal replacement therapy between January 1,
1988 and October 1, 1999. During the first 90 days
of renal replacement therapy, 51,398 (6.7%) patients
died, and 624 (0.1%) underwent PTX. These patients
were excluded from analysis. Furthermore, 9826 (1.3%)
patients younger than 18 years old, and 37,428 (4.9%)
patients with incomplete data regarding modality or pri-
mary cause of ESRD were excluded. Finally, 199,887
(26.0%) patients were excluded because fee-for-service
Medicare was not their primary payer 90 days after the
initiation of dialysis. Following these exclusions, 470,016
patients were available for analysis. Patients whose pri-
mary payer was Medicare tended to be older than those
with other insurance; however, other baseline character-
istics were similar among patients covered by Medicare
and patients excluded from study on the basis of other
insurance coverage.
From the eligible patient pool, 4844 patients undergo-
ing a first PTX while receiving hemodialysis or peritoneal
dialysis were identified. A suitable matched control pa-
tient not undergoing PTX was found for 4558 (93.3%)
of these patients. The remaining 286 unmatched PTX
patients were excluded. Excluded, unmatched patients
tended to be younger, and were more likely to be of race
other than Caucasian or African American, to be receiv-
ing peritoneal dialysis rather than hemodialysis, and to


















Fig. 1. Kaplan-Meier estimates of cumulative survival among patients
undergoing or not undergoing parathyroidectomy (PTX).
result, excluded, unmatched PTX patients had lower mor-
tality rates than PTX who were matched.
The completed matched study cohort was relatively
young (Table 1), with a high proportion of nondiabetic
patients, as compared to the general United States dialy-
sis population. The median hospital stay associated with
PTX was 7 days (intraquartile range, 5–11 days). Among
a subgroup of PTX patients and matched controls with a
PTX date after January 1, 1994, mean injectable calcitriol
use in the year prior to the PTX date was 4.63 lg/month
among PTX patients, and 4.15 lg/month among matched
controls (P value for comparison, 0.002).
Within the first 30 postoperative days there were 142
deaths among patients undergoing PTX (30-day postop-
erative mortality rate, 3.1%). In comparison, 1.2% (95%
CI 0.9–1.6) of matched control patients not undergoing
PTX died during the same 30-day period. Postoperative
deaths among PTX patients were classified as cardiovas-
cular (49.3%) and infectious (18.3%), with the remainder
due to a variety of illnesses, or not classified.
Median follow-up times were 2.9 years (intraquartile
range, 1.5–4.8 years) in the PTX group, and 2.7 years (in-
traquartile range, 1.4–4.4 years) in the matched control
group. Survival was initially higher among patients not
undergoing PTX, then became equal 587 days from the
date of surgery (Fig. 1). After 587 days, a higher propor-
tion of patients undergoing PTX remained alive through-
out follow-up. Median survival was 53.4 months (95% CI
51.2–56.4) in the PTX group and 46.8 months (95% CI
44.7–48.9) in the matched control group, a difference of
6.6 months.
As compared to matched controls, patients undergo-
ing PTX experienced an early increase in mortality risk
within 90 days of surgery, followed by a gradual decline in
the relative risk of death (Table 2). Relative risks of death
0 to 30, and 30 to 90 days following PTX were 2.72 (95%
CI 2.12–3.48) and 1.45 (95% CI 1.23–1.72), respectively,
compared to matched control patients. Approximately
90 days after surgery, the instantaneous hazard (or risk) of
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Table 2. Relative risk of mortality following parathyroidectomy by




Time from PTX Control Adjusted RRa
PTX date patients patients (95% CI) P value
0–30 days 385.8 (142) 148.0 (55) 2.72 (2.12, 3.48) <0.001
30–90 days 257.7 (182) 179.5 (130) 1.45 (1.23, 1.72) <0.001
90 days–1 year 159.5 (474) 184.3 (556) 0.90 (0.81, 0.99) 0.031
1 year–3 years 145.8 (884) 177.5 (1038) 0.85 (0.78, 0.92) <0.001
>3 years 147.8 (753) 174.0 (757) 0.85 (0.75, 0.97) 0.014
aControl patients matched to PTX patients by age, race, gender, primary cause
of ESRD, dialysis duration, dialysis modality at PTX, transplantation history,
and the date of initiation of renal replacement therapy, and further adjusted for
age, dialysis duration, and dialysis modality subsequent to PTX.
Table 3. Association between parathyroidectomy and 90-day




PTX (number of deaths) Adjusted relative
PTX Control risk of mortalitya
Patients patients (95% CI)
Overall 301.6 (324) 168.8 (185) 1.84 (1.52, 2.22)
Age
<40 years 131.4 (52) 70.5 (28) 1.82 (1.14, 2.93)
40–60 years 280.9 (115) 157.7 (65) 1.91 (1.38, 2.65)
>60 years 583.0 (157) 321.1 (92) 1.85 (1.41, 2.42)
Race
Caucasian 350.4 (182) 209.3 (111) 1.71 (1.34, 2.19)
African American 252.9 (133) 132.6 (71) 1.98 (1.47, 2.67)
Dialysis duration
0–1 years 526.4 (76) 209.0 (37) 2.53 (1.57, 4.06)
1–3 years 288.6 (105) 151.7 (56) 1.85 (1.25, 2.74)
3 or more years 252.5 (143) 167.4 (92) 1.52 (1.15, 2.01)
Cause of ESRD
Diabetes 604.5 (121) 285.5 (60) 2.12 (1.54, 2.93)
All other causes 232.2 (203) 141.1 (125) 1.71 (1.36, 2.16)
Dialysis modality
Hemodialysis 303.3 (266) 170.1 (152) 1.85 (1.51, 2.27)
Peritoneal dialysis 329.7 (58) 205.7 (31) 1.77 (1.12, 2.80)
aControl patients matched to PTX patients by age, race, gender, primary cause
of ESRD, dialysis duration, dialysis modality at PTX, transplantation history,
and the date of initiation of renal replacement therapy, and further adjusted for
age, dialysis duration, and dialysis modality subsequent to PTX.
death fell considerably among patients undergoing PTX.
Relative mortality rates were approximately 10% lower
among PTX patients between 90 days and 1 year follow-
ing surgery, and were approximately 15% lower through-
out the remainder of follow-up. Including baseline
calcitriol dose in the multivariate models did not change
mortality estimates for PTX.
To identify particular patient subgroups that might be
at highest risk, or incur the greatest benefit from PTX, the
relative mortality risk associated with PTX was analyzed
among patient subgroups (Tables 3 and 4). Short- and
long-term mortality rates were defined as 0 to 90 days,
and greater than 90 days from the date of PTX, respec-
tively. The short-term relative risk of death was higher
Table 4. Association between parathyroidectomy and long-term
mortality rates by patient subgroups
Mortality rate per
1000 person-years 90 days
following PTX through
follow-up (number of deaths) Adjustedrelative risk
PTX Control of mortalitya
Patients patients (95% CI)
Overall 149.4 (2111) 177.9 (2351) 0.87 (0.80, 0.94)
Age
<40 years 76.7 (466) 96.4 (539) 0.78 (0.66, 0.92)
40–60 years 163.7 (874) 187.0 (920) 0.88 (0.78, 1.00)
>60 years 283.6 (771) 329.9 (892) 0.89 (0.77, 1.03)
Race
Caucasian 178.0 (1142) 201.5 (1214) 0.90 (0.80, 1.01)
African American 126.8 (931) 157.4 (1077) 0.84 (0.75, 0.94)
Dialysis duration
0–1 years 182.9 (340) 193.1 (433) 1.07 (0.84, 1.36)
1–3 years 157.4 (773) 175.1 (805) 0.96 (0.81, 1.12)
3 or more years 135.6 (998) 174.6 (1113) 0.79 (0.70, 0.89)
Cause of ESRD
Diabetes 261.3 (508) 283.8 (573) 0.96 (0.81, 1.14)
All other causes 131.5 (1603) 158.8 (1778) 0.84 (0.77, 0.92)
Dialysis modality
Hemodialysis 154.0 (1465) 185.9 (1684) 0.87 (0,79, 0.95)
Peritoneal dialysis 163.8 (159) 205.8 (181) 0.86 (0.70, 1.05)
aControl patients matched to PTX patients by age, race, gender, primary cause
of ESRD, dialysis duration, dialysis modality at PTX, transplantation history,
and the date of initiation of renal replacement therapy, and further adjusted for
age, dialysis duration, and dialysis modality subsequent to PTX.
among diabetic patients, African American patients, and
patients who had received dialysis for less than 1 year
(Table 3). Short-term relative mortality risks did not dif-
fer appreciably by age or dialysis modality, nor did they
differ by gender, or whether a patient had previously un-
dergone renal transplantation. After 90 days the relative
risk of death associated with PTX was estimated to be
13% lower than that of matched control patents among
the overall study cohort (Table 4). Relative risks of death
tended to be lower among patients younger than 40 years
of age, and those who had received dialysis for greater
than 3 years. However, differences among subgroups in
their response to PTX were not statistically distinguish-
able. The apparent lack of long-term benefit associated
with PTX among diabetic patients was due to the fact that
diabetics incurred a continually increased risk of death for
up to 1 year following surgery. Among diabetic patients,
the relative risk of death between 90 days and 1 year
following PTX was 1.20 (95% CI 0.93–1.55), while the
relative risk of death greater than 1 year following PTX
was 0.79 (95% CI 0.63–1.00).
DISCUSSION
In this observational study, we found PTX to be asso-
ciated with lower long-term risks of mortality compared
to matched control patients not undergoing PTX. These
data suggest that control of SHPTH is likely to play an
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important role in the long-term outcome of chronic dial-
ysis patients.
Recent evidence has demonstrated important links be-
tween SHPTH and cardiovascular morbidity and mortal-
ity [12–15]. Excess circulating PTH concentrations lead
to increased cellular calcium uptake and cardiac fibrosis
experimentally [12, 13], and have been associated with an
increased risk of aortic calcification clinically [3]. Phos-
phate directly alters the phenotype of smooth muscle cells
in vitro, leading to the expression of bone matrix proteins
[15]. The resulting medial vessel wall calcification leads
to increased arterial stiffness, widened pulse pressures,
aggravation of left ventricular hypertrophy, and inade-
quate tissue perfusion [16]. Excess serum levels of phos-
phate, the calcium-phosphate product, and PTH have
been associated with an increased risk of all-cause [14]
and cardiovascular-specific [2] mortality among ESRD
patients. Given the link between SHPTH and cardio-
vascular disease, it would be expected that therapeutic
measures to attenuate SHPTH would positively impact
survival. PTX leads to immediate and dramatic reduc-
tions in circulating concentrations of PTH, calcium, and
phosphate in more than 95% of patients undergoing
surgery [17–19]. Although serologic data are not avail-
able for this population-based analysis, we hypothesize
that long-term levels of PTH, calcium, and phosphate
are, on average, lower among patients undergoing PTX
compared to matched control patients not undergoing
PTX.
A second mechanism by which PTX may lower long-
term mortality is by reducing exposure to medical ther-
apy prescribed to attenuate PTH and phosphate excess.
Although PTX may result in an initial increase in
calcium supplementation for postsurgical hypocalcemia
[20], it would be expected that long-term exposure
to calcium-containing binders might decrease following
PTX. Higher doses of oral calcium binders have been as-
sociated with the extent of coronary artery calcification
in a cohort of young ESRD patients [5].
Finally, it is possible that PTX contributes to lower
long-term mortality rates by moderating hypertension.
PTX has been observed to reduce blood pressure and
improve anemia among patients with ESRD [7, 18].
In a series of 21 patients undergoing PTX, significant
reductions in systolic and diastolic blood pressure of
9.4 mm Hg and 3.7 mm Hg were reported 18 months after
surgery, respectively [7]. In another series of 45 ESRD pa-
tients undergoing PTX, mean reductions of 12.0 mm Hg
and 6.2 mm Hg in systolic and diastolic blood pressure
were reported 1 year following PTX, respectively [18].
These authors also found that mean hemoglobin levels
increased significantly by 1.1 g/dL following PTX [18].
While long-term survival was found to be lower fol-
lowing PTX, we observed a 30-day postoperative mor-
tality rate of 3.1%, which is comparable to other studies
of surgical mortality in the dialysis population. Single-
center estimates of mortality following PTX are highly
variable, but generally consistent with our findings [8, 10,
19, 21]. For example, a retrospective chart review from the
University of Michigan reported 3 postoperative deaths
among 80 ESRD patients undergoing PTX between 1969
and 1992 (postoperative mortality rate 3.8%) [8], and a
case series of 20 consecutive patients undergoing PTX
for renal hyperparathyroidism in Germany reported 1
death within 6 days of surgery [21]. In contrast, a series of
1053 patients undergoing PTXs from a single institution
in Japan reported only 1 postoperative death [10]. Patient
selection, regional differences in referral for PTX, and
variability arising from small sample sizes likely account
for the variation noted among previous case series.
Potential factors contributing to early mortality follow-
ing PTX include the toxic effects of longstanding SHPTH,
metabolic disturbances following PTX, general sensitiv-
ity of ESRD patients to surgical procedures, poor com-
pliance among persons with longstanding SHPTH, and
selection of a subgroup of patients who are at imminent
risk of death. Typically, ESRD patients undergoing PTX
have longstanding PTH and phosphate excess, chronic
exposure to high doses of oral calcium binders and acti-
vated vitamin D, and, in some cases, hypercalcemia, all
factors that may increase the risk of death. Given the
link between these components of SHPTH and vascu-
lar calcification, it is possible that patients undergoing
PTX have considerable vascular compromise at the time
of surgery, placing them at high risk for postoperative
complications. Furthermore, PTX results in the “hungry
bone” syndrome [20], in which serum calcium levels fall
precipitously, prompting large doses of administered cal-
cium to maintain homeostasis. It is possible that elec-
trolyte shifts that occur as a result of the hungry bone
syndrome contribute to an increased risk of death follow-
ing PTX. Dialysis patients with refractory SHPTH may
be noncompliant with prescribed dietary recommenda-
tions and phosphate binders. As such, patients undergo-
ing SHPTH may be generally less compliant with other
important aspects of their medical care, placing them at
high risk for postoperative complications. The fact that
patients undergoing PTX tended to do relatively well in
the long-term raises the issue of whether dietary compli-
ance with phosphate may be less consequential once PTX
is performed.
A generally poor response to surgery among ESRD pa-
tients and the potential selection of high-risk patients for
PTX may also contribute to the substantial postoperative
risk of death that we observed. ESRD patients are known
to be at particularly high risk of mortality following surgi-
cal procedures. A recent study reported in-hospital mor-
tality rates of 8.6% and 6.4% among ESRD patients
undergoing coronary artery bypass grafting and percu-
taneous transluminal coronary angioplasty, respectively
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[22]. These postoperative mortality rates are markedly
higher than those reported among the general population
[23]. Further, ESRD patients undergoing a first cadaveric
renal transplant experienced a 2.8-fold increased risk of
death within the first 14 postoperative days compared to
patients awaiting surgery on the transplant waiting list
[24]. In addition to their overall sensitivity to surgical
procedures, some ESRD patients may undergo PTX for
the treatment of calciphylaxis [25], which carries a sub-
stantially elevated short-term risk of death [26]. Thus, it is
possible that the high risk of postoperative mortality fol-
lowing PTX derives from a particularly high-risk subset
of ESRD patients referred for PTX.
An important limitation of the present study is that
differences in patient characteristics among subjects un-
dergoing or not undergoing PTX may account for differ-
ences in mortality rates. Although control patients were
specifically matched to PTX patients by multiple clini-
cal factors, it is possible that patients undergoing PTX
differed from non-PTX patients by characteristics that
were not measured. ESRD patients who undergo elective
surgery are likely to be generally healthier than those not
undergoing surgery. Further, elevated levels of advanced
glycation end products and hyperglycemia significantly
blunt PTH secretion [27, 28], such that ESRD patients
with a vigorous PTH response might be expected to have
fewer cardiovascular risk factors. In this respect, the long-
term decline in the relative risk of death may derive from
presurgical health status, rather than from the potential
benefit of attenuating SHPTH. Importantly, the present
observational study does not intend to simulate a ran-
domized trial comparing PTX to medical management,
but instead focuses on long-term mortality rates following
PTX, while selecting the most relevant control population
to consider mortality rates in a relative context.
Other limitations of the present study include the lack
of specific laboratory or medication data. Without serum
PTH, phosphate, and calcium measurements, we cannot
discern which component of SHPTH might be respon-
sible for the observed survival data, or which levels of
serum markers may be associated with the greatest risks
and benefits of surgery. The restriction of the study co-
hort to those patient covered by Medicare, while neces-
sary to perform analyses of USRDS data, reduces the
generalizability of our results to those dialysis patients
receiving Medicare. Because PTX was defined using the
USRDS procedure data, no proper method of identifying
non-Medicare patients who undergo PTX are available to
study how the relative risk of death following PTX might
vary by Medicare status. Other studies utilizing different
data sources may be able to help answer these questions
in the future.
The selection of ESRD patients on the date of PTX re-
sulted in a cohort of relatively long-term survivors on re-
nal replacement therapy. While the selection of long-term
survivors may limit the generalizability of our results, our
findings are applicable to those ESRD patients consider-
ing PTX, who are often long-term survivors on dialysis.
It is important to note that mortality risks that were an-
alyzed greater than 3 years from the PTX date apply to
patients receiving PTX relatively early in the study and,
thus, under observation for greater than 3 years following
PTX. Important strengths of the current study include the
large sample of incident PTXs analyzed, providing ade-
quate power to accurately estimate mortality risks over
time, and the use of a national sample, which is not biased
by practice patterns of a particular region or health care
institution.
CONCLUSION
PTX performed among dialysis patients is associated
with an increased postoperative risk of death, followed by
a gradual decline in the relative risk of mortality. Survival
was initially lower among patients undergoing PTX un-
til 587 days following surgery, at which time survival was
higher in the PTX group. These data should be integrated
into the clinical decision-making process of referring dial-
ysis patients for surgery to correct SHPTH.
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